Payment overview · 2025
General Payments
$98.45
6 reported records · 3 companies
Healthcare provider profile · identity verified
Brian Parker, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CULLMAN, AL · NPI 1174977383
Verified facts
What the public records show
CMS Open Payments records show Brian Parker, M.D. received $98.45 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 48.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.09 | 48.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.67 | 37.2% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.69 | 13.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $98.45 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.09 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.09 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
161 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 619 | 187 |
| Levothyroxine Sodium | Levothyroxine Sodium | 590 | 160 |
| Pantoprazole Sodium | Pantoprazole Sodium | 484 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 463 | 133 |
| Montelukast Sodium | Montelukast Sodium | 436 | 127 |
| Omeprazole | Omeprazole | 410 | 124 |
| Losartan Potassium | Losartan Potassium | 395 | 127 |
| Lisinopril | Lisinopril | 350 | 106 |
| Gabapentin | Gabapentin | 324 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 313 | 78 |
| Tramadol Hcl | Tramadol Hcl | 308 | 62 |
| Meloxicam | Meloxicam | 307 | 99 |
| Trazodone Hcl | Trazodone Hcl | 274 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 76 |
| Metformin Hcl | Metformin Hcl | 260 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 260 | 85 |
| Furosemide | Furosemide | 243 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 241 | 71 |
| Famotidine | Famotidine | 221 | 81 |
| Escitalopram Oxalate | Escitalopram Oxalate | 205 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 203 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 202 | 58 |
| Prednisone | Prednisone | 202 | 145 |
| Sertraline Hcl | Sertraline Hcl | 200 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 191 | 66 |
| Pioglitazone Hcl | Pioglitazone Hcl | 179 | 49 |
| Potassium Chloride | Potassium Chloride | 176 | 50 |
| Simvastatin | Simvastatin | 171 | 49 |
| Carvedilol | Carvedilol | 167 | 51 |
| Eliquis | Apixaban | 161 | 31 |
| Ozempic | Semaglutide | 157 | 31 |
| Pregabalin | Pregabalin | 156 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 147 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 141 | 33 |
| Allopurinol | Allopurinol | 138 | 31 |
| Clonazepam | Clonazepam | 134 | 16 |
| Farxiga | Dapagliflozin Propanediol | 134 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 38 |
| Benazepril Hcl | Benazepril Hcl | 128 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 31 |
| Metformin Hcl Er | Metformin Hcl | 122 | 39 |
| Alprazolam | Alprazolam | 121 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 120 | 30 |
| Donepezil Hcl | Donepezil Hcl | 118 | 38 |
| Glimepiride | Glimepiride | 117 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 116 | 98 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 19 |
| Trulicity | Dulaglutide | 108 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 105 | 33 |
| Buspirone Hcl | Buspirone Hcl | 97 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 32 |
| Mounjaro | Tirzepatide | 94 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 31 |
| Methocarbamol | Methocarbamol | 90 | 20 |
| Celecoxib | Celecoxib | 89 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 21 |
| Atenolol | Atenolol | 84 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 19 |
| Bupropion Xl | Bupropion Hcl | 81 | 22 |
| Fenofibrate | Fenofibrate | 81 | 22 |
| Xarelto | Rivaroxaban | 81 | 12 |
| Ezetimibe | Ezetimibe | 75 | 25 |
| Propranolol Hcl | Propranolol Hcl | 72 | 18 |
| Lorazepam | Lorazepam | 70 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 67 | 22 |
| Januvia | Sitagliptin Phosphate | 67 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 67 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 27 |
| Telmisartan | Telmisartan | 65 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 19 |
| Sucralfate | Sucralfate | 63 | 20 |
| Mirtazapine | Mirtazapine | 62 | 14 |
| Estradiol | Estradiol | 61 | 12 |
| Glipizide | Glipizide | 60 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 18 |
| Temazepam | Temazepam | 56 | suppressed |
| Baclofen | Baclofen | 54 | suppressed |
| Spironolactone | Spironolactone | 53 | 16 |
| Clonidine Hcl | Clonidine Hcl | 51 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 48 | 13 |
| Ondansetron Odt | Ondansetron | 48 | 21 |
| Finasteride | Finasteride | 47 | 16 |
| Jardiance | Empagliflozin | 47 | 13 |
| Glipizide Er | Glipizide | 46 | 15 |
| Memantine Hcl | Memantine Hcl | 46 | 14 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 38 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 32 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 11 |
| Ibuprofen | Ibuprofen | 30 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 20 |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Trandolapril | Trandolapril | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 18 |
| Ramipril | Ramipril | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 20 |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 15 |
| Digoxin | Digoxin | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Piroxicam | Piroxicam | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $98.45 · 6 records | ABBVIE INC. | NEXLETOL, PAXLOVID, QULIPTA, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error